LAMPUGNANI
FARMACEUTICI

DOI https://doi.org/10.4081/aiua.2019.4.251

Mattia Sibona *
Department of Urology, Department of Surgical Sciences, A.O.U. Città della Salute e della Scienza di Torino, Molinette Hospital, University of Turin, Italy.
Paolo Destefanis
Department of Urology, Department of Surgical Sciences, A.O.U. Città della Salute e della Scienza di Torino, Molinette Hospital, University of Turin, Italy.
Marco Agnello
Department of Urology, Department of Surgical Sciences, A.O.U. Città della Salute e della Scienza di Torino, Molinette Hospital, University of Turin, Italy.
Beatrice Lillaz
Department of Urology, Department of Surgical Sciences, A.O.U. Città della Salute e della Scienza di Torino, Molinette Hospital, University of Turin, Italy.
Mattia Giuliano
Department of Urology, Department of Surgical Sciences, A.O.U. Città della Salute e della Scienza di Torino, Molinette Hospital, University of Turin, Italy.
Tommaso Cai
Department of Urology, Santa Chiara Regional Hospital, Trento, Italy.
Paolo Gontero
Department of Urology, Department of Surgical Sciences, A.O.U. Città della Salute e della Scienza di Torino, Molinette Hospital, University of Turin, Italy.
(*) Corresponding Author:
Mattia Sibona | mattia.sibona@gmail.com

Abstract

Objectives: Chronic prostatitis syndrome is a bothering and poorly understood condition. Many patients report genitourinary pain and Lower Urinary Tract Symptoms as a main complaint. Many different pharmacological or behavioural therapies are prescribed in daily clinical practice, but efficacy data are still lacking. The aim of our study was to test the efficacy and safety of a transrectal delivered association of Boswellia resin extract and propolis derived polyphenols for the relief of prostatitis – like symptoms.

Materials and methods: Patients affected by chronic/recurrent prostatitis – like symptoms were prospectively enrolled in our study from December, 2016 to December, 2018. Patients were screened at baseline through clinical examination and validated questionnaires administration: Chronic Prostatitis Symptom Index (CPSI), International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF). Inclusion criteria were: age ≥ 18; prostatitis symptoms persisting for at least 3 of the last 6 months; CPSI pain domain score ≥ 5; previous negative Meares-Stamey test. Treatment consisted on the administration of 1 suppository containing Boswellia resin extract and propolis derived polyphenols, once a day for 20 days. The primary endpoint of the study was the improvement of quality of life after treatment, defined by a reduction of ≥ 2 points, or ≥ 25%, of mean CPSI pain domain score, compared to baseline. Secondary endpoints were the improvement of post-treatment CPSI total score and the analysis of treatment – related adverse events. All patients were re-evaluated 1 month after treatment.

Results: 40 patients were enrolled in our study. Median age (Inter – Quartile Range IQR) was 51.5 (41.5-63.2) years. Mean baseline CPSI scores were: 22.15 (total score), 9.67 (pain domain), 5.15 (micturition domain) and 7.35 (quality of life domain), respectively. No significant adverse events were reported. At 1 month follow-up, CPSI scores appeared modified as follows: 16.40 (total score, p = 0.001); 6.92 (pain domain; p = 0.001; 4.02 (micturition domain, p = 0.09); 5.45 (quality of life domain, p = 0.002). Mean CPSI pain domain score reduction was -2.75 points (-28.5%). Mean CPSI total score reduction was -5.75 points (-26%).

Conclusions: The association of Boswellia resin extract and propolis derived polyphenols can reduce genitourinary pain and then improve quality of life of men affected by bothersome prostatitis – like symptoms.

Published: Jan 14, 2020
Original Papers – Andrology
Vol 91 No 4 (2019)
Archivio Italiano di Urologia e Andrologia